SIETES :: 92793 citas

Resultados de la búsqueda por PSICOFÁRMACOS REFINAR BÚSQUEDA

1.

Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]

2.

Iacobucci G. NHS prescribed record number of antidepressants last year. BMJ 2019;364:29 de marzo. [Ref.ID 103088]

3.

Brännström J, Lövheim H, Gustafson Y, Nordström P. Association between antidepressant drug use and hip fracture in older people before and after treatment initiation. JAMA Psychiatry 2019:2 de enero. [Ref.ID 103000]

4.

Hengartner MP. What is the threshold for a clinical minimally important drug effect?. BMJ Evidence-Based Medicine 2018;23:21 de noviembre. [Ref.ID 102912]

5.

Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]

6.

Grove K, Lewis AJ, Galbally M. Prenatal antidepressant exposure and child motor development: a meta-analysis. Pediatrics 2018;142:julio. [Ref.ID 102887]

7.

Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]

8.

Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rodevand L, Melle I, Andreassen OA, Molden E, Jönsson EG. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. J Psychiatr Res 2018:25 de septiembre. [Ref.ID 102832]

9.

El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. Characteristics of tianeptine exposures reported to the National Poison Data System — United States, 2000–2017. Morbidity and Mortality Weekly Report 2018;67:3 de agosto. [Ref.ID 102752]

10.

Thielking M. Poison control calls spike for unapproved drug that produces opioid-like highs. STAT Daily Recap 2018:2 de agosto. [Ref.ID 102737]

11.

Thielking M. Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can’t confirm. STAT Daily Recap 2018:2 de agosto. [Ref.ID 102736]

12.

Huo Y-L, Qiao J-M, Gao S. Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018;84:abril. [Ref.ID 102680]

13.

Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018;361:23 de mayo. [Ref.ID 102648]

14.

Maxwell CJ, Campitelli MA, Hogan DB, Diong C, Austin PC, Amuah JE, Lapane K, Seitz DP, Gill SS, Gruneir A, Wodchis WP, Bronskill SE. Relevance of frailty to mortality associated with the use of antipsychotics among community-residing older adults with impaired cognition. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102632]

15.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

16.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

17.

Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A. Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 2018;74:mayo. [Ref.ID 102512]

18.

Cipriani A, Furukwa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. . Lancet 2018;391:7 de abril. [Ref.ID 102476]

19.

Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]

20.

Burcu M, Zito JM, Safer DJ, Magder LS, dos-Reis S, Shaya FT, Rosenthal GL. Association of antidepressant medications with incident type 2 diabetes among Medicaid-insured youths. JAMA Pediatrics 2017:16 de octubre. [Ref.ID 102122]